Command Palette

Search for a command to run...

THEMISMED

127.75-2.34%
Market Cap
₹1,205.27 Cr
Stock P/E
-132.85
ROCE
10.37%
ROE
7.65%
Book Value
₹42.21

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Themis Medicare Ltd. exhibits moderate growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it is not the highest performer in any category, it maintains a solid position with low debt and reasonable EBITDA margins, suggesting stability. However, several peers outperform it in growth and return metrics, indicating competitive pressure.

Key Points
  • Themis Medicare has a moderate revenue growth of 7.74% YoY, but lower than several peers.
  • It has a relatively low PE ratio of 38.57, but this does not translate into high profitability, with a ROE of 7.65%.
  • The company maintains a low debt-to-equity ratio of 0.2061, suggesting financial stability.
Top Performers
Mankind Pharma Ltd.

Highest revenue growth YoY at 18.12% and strong profitability metrics.

Cipla Ltd.

Best overall balance of growth, profitability, and low valuation metrics.

Dr. Reddy's Laboratories Ltd.

Strong profitability with a ROE of 21.76% and attractive PEG of 0.19.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.